Supply High Purity 99% Pharmaceutical Chemical Raw Material Posaconazole CAS 171228-49-2

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: HMJ-Posaconazole
• Color: White
• Mf: C37h42f2n8o4
• Einecs: 682-747-8
• Test: HPLC
• MW: 700.78
• CAS: 171228-49-2
• Shelf Life: 2 Years
• Grade: Pharmaceutical Grade
• Transport Package: Ziplock Foil Bag. Drum
• Specification: 1kg Per Foil Bag, 10 Bags Per Carton, 25 Kg Per Dr
• Trademark: HMJ
• Origin: China
• Production Capacity: 200kg/Month

Product Description

High Purity 99% Pharmaceutical Chemical Raw Material Posaconazole CAS 171228-49-2 

Product Description

 

Product Name	High Purity 99% Pharmaceutical Chemical Raw Material Posaconazole CAS 171228-49-2
Appearance	White powder
Molecular formula	C37H42F2N8O4
Molecular weight	700.78
Keywords	Powder Posaconazole ,Price Posaconazole ; Pure Posaconazole
Shelf Life	24 months when properly stored
Storage	Keep in a cool, dry, dark location

Function

What is Posaconazole?

Posaconazole is a triazole antifungal drug. It is used for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or those with hematologic malignancies with prolonged neutropenia from chemotherapy. It is also used for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to itraconazole and/or fluconazole therapy. It is also used to treat invasive infections by Candida, Mucor, and Aspergillus species in severely immunocompromised patients.

Function of Posaconazole

Invasive aspergillosis,Fusarium infection,Chromoblastomycosis and mycetoma,Coccidioidomycosis,Oropharyngeal candidosis
Prophylaxis of invasive fungal infections in patients at serious risk
With the exception of oropharyngeal candidosis and prophylaxis, use is presently restricted to patients with disease that is refractory to other antifungal drugs, or who are intolerant to them.

Posaconazole, launched in the UK, is the newest member of the a zole class of antifungal agents to reach the market. It is indicated for the treatment and prophylaxis of a range of invasive fungal infections, including aspergillosis,fusariosis, chromoblastomycosis, mycetoma, and coccidiomycosis in patients who are refractory to, or intolerant of, standard therapy with amphotericin B and/or itracona zole. In the US, it is approved for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age who are at high risk of developing these infections due to being severely immunocompromised. Additionally, it is approved for the treatment of oropharyngeal candidiasis. Posacona zole has an expanded spectrum of activity over other members of the a zole antifungals. In addition to potent activity against refractory cases of aspergillosis and flucona zole-resistant Candida, it demonstrates activity against Zygomycetes.

 

Detailed Photos

 

 

 

Related Product

Packaging & Shipping